

Seeking Novel Druggable Targets in Neuroinflammation and Neuroimmunity

Servier, a leading international pharmaceutical company, is seeking novel therapeutic proposals that **target neuroinflammation and/or neuroimmunity** in central nervous system and/or peripheral nervous system diseases. The team is particularly interested in approaches that have an already **identified target**, demonstrate the ability to **counteract these pathological conditions**, and offer a **well-supported and differentiating pharmacological strategy** for treatment.



Approaches of Interest:

- **Diseases of interest** are ALS (sporadic form and neuroinflammation associated with genetic form), autoimmune myasthenia gravis, chronic inflammatory demyelinating polyneuropathies, autoimmune nodopathies, autoimmune epilepsy, and autoimmune encephalitis
- Other neuroinflammatory/ neuroimmune diseases will be considered but as a lower priority and only if they have a clear identified target. In all cases, the eligible patient population should be over 500 individuals
- Modalities of interest include **small molecules, antibodies, and antisense oligonucleotides**
- All targets and mechanisms of action related to neuroinflammation and/or neuroimmunity are in scope
- Drug repurposing is of interest, provided there is clearly demonstrated involvement and proof of concept for one of the diseases of interest

Out of Scope:

- Cell therapy, gene therapy, and medical devices
- Broad or not-targeted anti-inflammatory approaches

Developmental Stages of Interest:

- Opportunities up to late preclinical stage are of interest, provided there is clear proof of concept, at least *in vitro*
- Opportunities with *in vivo* proof of concept will be given priority

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications or supporting materials/ experimental data. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Opportunities sought

-  Technologies
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **1st December 2025 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

